INMB INmune Bio

INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer’s Drug Discovery

INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer’s Drug Discovery
EN
05/10/2020

Underlying

INMBINmune Bio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INmune Bio

 PRESS RELEASE
Free
INMB INMUNE BIO

INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Busi...

INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update Company to Host Conference Call Today, October 30, at 4:30pm ET BOCA RATON, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2025 and provides a business update. Q3 2025 and Recent Corporate Highlights   CORDStrom™ Platform: Announced successful completion o...

October 30, 2025 1 EN
 PRESS RELEASE
Free
INMB INMUNE BIO

INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Pro...

INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 23, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), INmune Bio Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces that it will host a conference call on Thursday, October 30, 2025 at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2025 and to provide a corporate update. ...

October 23, 2025 1 EN
 PRESS RELEASE
Free
INMB INMUNE BIO

INmune Bio to Participate in Dermatologic Rare Disease Panel at the Ma...

INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025 Boca Raton, FL, Oct. 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces that David Moss, Chief Executive Officer will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit presented by Maxim Group LLC.  The Summit is being held on October 22 – 23, 2025 at the Hard Rock Hotel in New York City. The panel will be moderated by Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Re...

October 14, 2025 1 EN
 PRESS RELEASE
Free
INMB INMUNE BIO

INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Al...

INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal Boca Raton, FL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces the submission of a manuscript detailing the results of its Phase 2 MINDFuL trial. The manuscript, titled, “XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial,” has been submitted for peer review to npj Dementia, a Natu...

September 29, 2025 1 EN
 PRESS RELEASE
Free
INMB INMUNE BIO

INmune Bio Announces Successful Completion of First Commercial Pilot-S...

INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult BOCA RATON, Fla., Sept. 15, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune” or “the Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced the successful completion of its first full-scale pilot commercial manufacturing run of CORDStrom™, an off-the-shelf, allogeneic, umbilical cord tissue-derived mesenchymal stromal cell thera...

September 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch